Foreign-Trade Zone (FTZ) 7-Mayaguez, Puerto Rico, Authorization of Production Activity, IPR Pharmaceuticals, Inc. (Pharmaceutical Products), Canovanas, Puerto Rico, 37738 [2021-15126]

Download as PDF 37738 Federal Register / Vol. 86, No. 134 / Friday, July 16, 2021 / Notices 25, 2021. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15-day period to September 9, 2021. A copy of the application will be available for public inspection in the ‘‘Reading Room’’ section of the FTZ Board’s website, which is accessible via www.trade.gov/ftz. For further information, contact Qahira El-Amin at Qahira.El-Amin@ trade.gov. Dated: July 12, 2021. Andrew McGilvray, Executive Secretary. [FR Doc. 2021–15128 Filed 7–15–21; 8:45 am] BILLING CODE 3510–DS–P DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [B–23–2021] Foreign-Trade Zone (FTZ) 7— Mayaguez, Puerto Rico, Authorization of Production Activity, IPR Pharmaceuticals, Inc. (Pharmaceutical Products), Canovanas, Puerto Rico On March 15, 2021, IPR Pharmaceuticals, Inc., submitted a notification of proposed production activity to the FTZ Board for its facility within FTZ 7, in Canovanas, Puerto Rico. The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the Federal Register inviting public comment (86 FR 15642, March 24, 2021). On July 13, 2021, the applicant was notified of the FTZ Board’s decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board’s regulations, including Section 400.14. Dated: July 13, 2021. Andrew McGilvray, Executive Secretary. DEPARTMENT OF COMMERCE International Trade Administration [C–533–884] Glycine From India: Preliminary Results of Countervailing Duty Administrative Review; 2018–2019 Enforcement and Compliance, International Trade Administration, Department of Commerce. SUMMARY: The Department of Commerce (Commerce) preliminarily determines that countervailable subsidies are being provided to producers and exporters of glycine from India for the period of review (POR) September 4, 2018, through December 31, 2019. The preliminary net subsidy rates are listed below in the section titled ‘‘Preliminary Results of Administrative Review.’’ Interested parties are invited to comment on these preliminary results. DATES: Applicable July 16, 2021. FOR FURTHER INFORMATION CONTACT: Davina Friedmann, AD/CVD Operations, Office VI, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482–0698. SUPPLEMENTARY INFORMATION: AGENCY: Background On August 6, 2020, Commerce published a notice of initiation of administrative review of the countervailing duty order on glycine from India.1 On March 2, 2021, Commerce extended the deadline for issuing the preliminary results of review.2 The revised deadline for these preliminary results of review is now June 30, 2021. For a complete description of the events that followed the initiation of this review, see the Preliminary Decision Memorandum.3 A list of topics discussed in the Preliminary Decision Memorandum is included at Appendix I to this notice. The Preliminary Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance’s Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS). ACCESS is available to registered users at http:// access.trade.gov. In addition, a complete version of the Preliminary Decision Memorandum can be accessed directly at http://enforcement.trade.gov/frn/. Scope of the Order The merchandise covered by the order is glycine from India. For a complete description of the scope of the order, see the Preliminary Decision Memorandum. Methodology Commerce is conducting this review in accordance with section 751(a)(1)(A) of the Tariff Act of 1930, as amended (the Act). For each of the subsidy programs found countervailable, we preliminarily determine that there is a subsidy, i.e., a financial contribution that gives rise to a benefit to the recipient, and the subsidy is specific.4 For a full description of the methodology underlying our conclusions, see the Preliminary Decision Memorandum. On June 11, 2021, we initiated an investigation of newly alleged subsidy programs.5 Because we did not receive information from the Government of India, Avid Organics Private Limited (Avid), or Kumar Industries (India) (Kumar) related to the new subsidy programs in time to evaluate them for purposes of these preliminary results of review, we intend to issue postpreliminary review results that incorporate these programs.6 Companies Not Selected for Individual Review For companies not selected for individual review, because the 2019 subsidy rates calculated for Avid and Kumar were above de minimis and not based on facts available, we have preliminarily calculated a subsidy rate based on a weighted-average of the subsidy rates calculated for Avid and Kumar using publicly ranged sales data submitted by respondents.7 For 2018, we preliminarily assigned to the companies not individually examined a subsidy rate of 3.58 percent, which is the 2018 subsidy rate calculated for Avid for these preliminary results of [FR Doc. 2021–15126 Filed 7–15–21; 8:45 am] 1 See Initiation of Antidumping and Countervailing Duty Administrative Reviews, 85 FR 47731 (August 6, 2020). 2 See Memorandum, ‘‘Glycine from India: Extension of Time Limit for Preliminary Results,’’ dated March 2, 2021. 3 See Memorandum, ‘‘Decision Memorandum for the Affirmative Preliminary Determination: First Administrative Review of Glycine from India,’’ dated concurrently with, and hereby adopted by, this notice (Preliminary Decision Memorandum). jbell on DSKJLSW7X2PROD with NOTICES BILLING CODE 3510–DS–P VerDate Sep<11>2014 17:26 Jul 15, 2021 Jkt 253001 PO 00000 Frm 00011 Fmt 4703 Sfmt 4703 4 See sections 771(5)(B) and (D) of the Act regarding financial contribution; section 771(5)(E) of the Act regarding benefit; and section 771(5A) of the Act regarding specificity. 5 See Memorandum, ‘‘Administrative Review of the Countervailing Duty Order on Glycine from India; 2018–2019, New Subsidy Allegations,’’ dated June 17, 2021. 6 See Preliminary Decision Memorandum. 7 See Memorandum, ‘‘Calculation of Subsidy Rate for Non-Selected Companies,’’ dated June 30, 2021. E:\FR\FM\16JYN1.SGM 16JYN1

Agencies

[Federal Register Volume 86, Number 134 (Friday, July 16, 2021)]
[Notices]
[Page 37738]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-15126]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-23-2021]


Foreign-Trade Zone (FTZ) 7--Mayaguez, Puerto Rico, Authorization 
of Production Activity, IPR Pharmaceuticals, Inc. (Pharmaceutical 
Products), Canovanas, Puerto Rico

    On March 15, 2021, IPR Pharmaceuticals, Inc., submitted a 
notification of proposed production activity to the FTZ Board for its 
facility within FTZ 7, in Canovanas, Puerto Rico.
    The notification was processed in accordance with the regulations 
of the FTZ Board (15 CFR part 400), including notice in the Federal 
Register inviting public comment (86 FR 15642, March 24, 2021). On July 
13, 2021, the applicant was notified of the FTZ Board's decision that 
no further review of the activity is warranted at this time. The 
production activity described in the notification was authorized, 
subject to the FTZ Act and the FTZ Board's regulations, including 
Section 400.14.

    Dated: July 13, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-15126 Filed 7-15-21; 8:45 am]
BILLING CODE 3510-DS-P